drugset / Trial / NCT01817283

Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders

NCT01817283

Phase 1/2 Unknown 150 enrolled LI Taisheng
RandomizedCrossoverDouble-blindTreatment

Summary

This study is a prospective, multicenter, randomized, placebo-controlled clinical trial, to evaluate impact of Triptolide wilfordii on T cell immune activation and inflammation biomarkers in HIV-infected immunological non-responders.

Timeline

Start
2013-01
Primary completion
2014-07
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Triptolide Traditional medicine (herbal / TCM) 20 mg Oral
Background cART Unknown